Treatment of Vasomotor Symptoms

Abstract

The invention relates to a method for the treatment of vasomotor symptoms comprising the administration of a therpeutically effective amount of flibanserin.

1 . A method for the treatment of vasomotor symptoms comprising the administration of a therapeutically effective amount of flibanserin, or a pharmacologically acceptable acid addition salt, hydrate, or solvate, thereof. 
     
     
         2 . The method according to  claim 1 , wherein the vasomotor symptoms are vasomotor symptoms associated with the menopause. 
     
     
         3 . The method according to  claim 1 , wherein the vasomotor symptoms are vasomotor symptoms associated with surgically induced menopause. 
     
     
         4 . The method according to  claim 1 , wherein the vasomotor symptoms are vasomotor symptoms associated with iatrogenic induced menopause. 
     
     
         5 . The method according to  claim 1 , wherein the vasomotor symptoms are vasomotor symptoms associated with the use of medication, radiation, or chemotherapeutic agents. 
     
     
         6 . The method according to  claim 1 , wherein the vasomotor symptoms are selected from the group consisting of hot flashes, night sweats, mood swings, and irritability. 
     
     
         7 . The method according to  claim 1 , wherein the vasomotor symptoms are moderate to severe vasomotor symptoms associated with a natural or iatrogenic hypogonadal state in men. 
     
     
         8 . The method according to  claim 7 , wherein the vasomotor symptoms are vasomotor symptoms associated with the use of medication, radiation, or chemotherapeutic agents. 
     
     
         9 . The method according to  claim 7 , wherein the vasomotor symptoms are hot flashes in men. 
     
     
         10 . The method according to any one of the  claim 1  to  9  or  13  or  14 , wherein the flibanserin is administered as a pharmaceutically acceptable acid addition salt selected from the salts formed by succinic acid, hydrobromic acid, acetic acid, fumaric acid, maleic acid, methanesulphonic acid, lactic acid, phosphoric acid, hydrochloric acid, sulphuric acid, tartaric acid, citric acid, and mixtures thereof. 
     
     
         11 . The method according to any one of the  claim 1  to  9  or  13  or  14 , wherein the flibanserin is administered as flibanserin polymorph A. 
     
     
         12 . The method according to any one of the  claim 1  to  9  or  13  or  14 , wherein the flibanserin is administered in a dose range between 0.1 to 400 mg per day. 
     
     
         13 . The method according to  claim 4 , wherein the vasomotor symptoms are vasomotor symptoms associated with the use of medication, radiation, or chemotherapeutic agents. 
     
     
         14 . The method according to  claim 8 , wherein the vasomotor symptoms are hot flashes in men.